Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01085-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Breanne Mefford und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Vancomycin, Meropenem, Acute Kidney Injury, Cefepime. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) and vancomycin (VAN) are commonly used in combination for sepsis. Studies have shown an increased risk of acute kidney injury (AKI) with TZP and VAN compared to FEP or MEM. VAN guidelines recommend area under the curve (AUC) monitoring over trough (Tr) to minimize the risk of AKI. We investigated the association of AKI and MAKE-30 with the two VAN monitoring strategies when used in combination with TZP or FEP/MEM. Adult patients between 2015 and 2019 with VAN > 72 hours were included. Patients with AKI prior to or within 48 hours of VAN or baseline CrCl of ≤30 mL/min were excluded. Four cohorts were defined: FEP/MEM/Tr, FEP/MEM/AUC, TZP/Tr, and TZP/AUC. A Cox Proportional Hazard Model was used to model AKI as a function of the incidence rate of at-risk days, testing monitoring strategy as a treatment effect modification. Multivariable logistic regression was used to model MAKE-30. Overall incidence of AKI was 18.6%; FEP/MEM/Tr = 115 (14.6%), FEP/MEM/AUC = 52 (14.9%), TZP/Tr = 189 (26%), and TZP/AUC = 96 (17.1%) ( P < 0.001). Both drug group [(TZP; P = 0.0085)] and monitoring strategy [(Tr; P = 0.0007)] were highly associated with the development of AKI; however, the effect was not modified with interaction term [(TZP*Tr); 0.085)]. The odds of developing MAKE-30 were not different between any group and FEP/MEM/AUC. The effect of VAN/TZP on the development of AKI was not modified by the VAN monitoring strategy (AUC vs trough). MAKE-30 outcomes were not different among the four cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA.
- Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Kentucky, Lexington, Kentucky, USA.
- University of Kentucky Children's Hospital, Lexington, Kentucky, USA.
- Department of Computer Science, University of Kentucky, Lexington, Kentucky, USA.
ORCID-Profile: Breanne Mefford, Katie L Wallace, Melissa L Thompson Bastin
Förderung
- NCATS NIH HHS
Zitieren
APA
Mefford, B., Wallace, K. L., Donaldson, J. C., Bissell Turpin, B. D., Sen, P., Schadler, A. D., Liu, L. J., & Thompson Bastin, M. L. (2024). Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01085-23
Vancouver
Mefford B, Wallace KL, Donaldson JC, Bissell Turpin BD, Sen P, Schadler AD, et al. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01085-23
BibTeX
@article{Mefford2024,
author = {Mefford, Breanne and Wallace, Katie L and Donaldson, J Chris and Bissell Turpin, Brittany D and Sen, Parijat and Schadler, Aric D and Liu, Lucas J and Thompson Bastin, Melissa L},
title = {Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01085-23}
}
EUVIMED